AGM/EGMMay 8, 2026, 06:14 AM
SOPHiA GENETICS Names Ross Muken CEO; AGM Set for June 18
AI Summary
SOPHiA GENETICS announced its Annual General Meeting (AGM) for June 18, 2026, where shareholders will vote on key proposals including a significant leadership transition. Ross Muken, currently President, will be promoted to CEO effective July 1, 2026, with co-founder Dr. Jurgi Camblong transitioning to Executive Chair. The company reported a defining year of growth in 2025, with over 391,000 analyses conducted, 993 global customers, and a 115% net dollar retention. Adjusted gross margin expanded to 74.2%, and the company aims for adjusted EBITDA breakeven by the end of 2026, despite carrying forward a net loss of CHF 52.8 million for 2025.
Key Highlights
- Ross Muken will become CEO on July 1, 2026; Dr. Jurgi Camblong will transition to Executive Chair.
- Platform conducted over 391,000 analyses in 2025, reaching 993 customers globally.
- Net dollar retention increased to 115% in 2025, up from 104% in 2024.
- Adjusted gross margin expanded by 140 basis points to 74.2% in 2025.
- Company expects to approach adjusted EBITDA breakeven by end of 2026 and positive in H2 2027.
- Shareholders to vote on approving 2025 financial statements and carrying forward a net loss of CHF 52.8M.
- Proposals include re-election of Board members and approval of executive compensation.
- Proposed amendment to increase conditional share capital for employee participation to CHF 1,240,378.20.